Biohaven Pharmaceutical Holding Company Ltd.

(415) 506-6700
770 Lindaro Street, San Rafael, CA 94901
Business
Big Business

BioMarin is a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes

back to directoryBack to Directory

Related Posts:

BIOHAVEN: To Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA
BIOHAVEN: To Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA

March 30, 2020

In previously reported positive topline results from pivotal Phase 2/3 clinical trial in December 2019, vazegepant achieved statistical superiority to placebo on the co-primary regulatory endpoints of pain freedom and freedom from most bothersome symptom at 2 hours

Read more →
BIOHAVEN PHARMACEUTICALS: Biohaven’s Verdiperstat Receives FDA May Proceed Letter To Initiate Trial In Amyotrophic Lateral Sclerosis Conducted By The Healey Center For ALS At Mass General
BIOHAVEN PHARMACEUTICALS: Biohaven’s Verdiperstat Receives FDA May Proceed Letter To Initiate Trial In Amyotrophic Lateral Sclerosis Conducted By The Healey Center For ALS At Mass General

January 22, 2020

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a biopharmaceutical company with multiple late-stage neuroscience drug candidates in development, announced today that the U.S. Food and Drug Administration (FDA) has notified its collaborators at the Sean M. Healey & AMG Center for Amyotrophic Lateral Sclerosis (ALS) at Massachusetts General Hospital (MGH) that they may proceed with clinical investigation of verdiperstat, Biohaven's novel myeloperoxidase (MPO) inhibitor, in ALS.

Read more →

Trending

BAYER: U.S. FDA Approves Addition of Overall Survival and Other Secondary Endpoint Data to NUBEQA® (darolutamide) Prescribing Information
LOCATE BIO: CognitOss Granted FDA Breakthrough Device Designation
NORTHSTAR MEDICAL RADIOISOTOPES: Announces FDA Approval for Enhanced U.S. Mo-99 Radioisotope Production Capacity
KING & SPALDING: FDA and Life Sciences Team Adds Partner in Washington
FUNCTIONAL NEUROMODULATION: Announces Breakthrough Device Designation from the U.S. FDA for Deep Brain Stimulation for Alzheimer’s Disease
ULTROMICS: Receives Fda Clearance for a First-of-kind Solution in Echocardiography to Help Clinicians Diagnose Disease

The Weekly Newsletter

Sign-up for the Weekly Newsletter from FDA Reporter.